Depression with psychotic features has been shown to respond to selective serotonin reuptake inhibitors (SSRIs). The serotonin transporter (5-HTT) is a prime target for SSRIs. A functional polymorphism within the promoter region of the 5-HTT gene, leading to different transcriptional efficiency, was recently reported. We tested the hypothesis that allelic variation of the 5-HTT promoter could be related to the antidepressant response to fluvoxamine and/or augmentation with pindolol (a serotonin autoreceptors antagonist) which has been suggested as an augmentation therapy for nonresponders. One hundred and two inpatients with major depression with psychotic features were randomly assigned to treatment with a fixed dose of fluvoxamine and either placebo or pindolol for 6 weeks. Depression severity was assessed once a week using the Hamilton Depression Rating Scale. Allelic variation in each subject was determined using a PCR-based method. Data were analyzed with a three-way repeated measures analysis of variance. Both homozygotes for the long variant (l/l) of the 5-HTT promoter and heterozygotes (l/s) showed a better response to fluvoxamine than homozygotes for the short variant (s/s). In the group treated with fluvoxamine plus pindolol all the genotypes acted like l/l treated with fluvoxamine alone. Fluvoxamine efficacy in delusional depression seems to be related to allelic variation within the promoter of the 5-HTT gene. Even though other factors may be implicated, genotyping at 5-HTT promoter may represent a promising tool to individualize the pharmacological treatment of depression.
Introduction
Depression with psychotic features is a particularly severe form of mood disorder. It is characterized by high recurrence rates, greater long-term morbidity, poor placebo and low response rate to tricyclic antidepressants alone. 1 Effective treatment can consist of antidepressants combined with neuroleptics or ECT.
We have recently reported that full doses of the selective serotonin reuptake inhibitors (SSRIs) fluvoxamine and sertraline as monotherapy are effective in the treatment of delusional depression, 2,3 thus suggesting the involvement of serotonin (5-HT) in the pharmacotherapy of this disorder.
The serotonin transporter (5-HTT) plays a critical role in the termination of 5-HT neurotransmission and represents the prime target for SSRIs. The human 5-HTT is encoded by a single gene on chromosome 17q11.2-12. 4 Recently, a functional polymorphism in the transcriptional control region upstream of the 5- It has been demonstrated that the long (l) and short (s) variants of this 5-HTT gene-linked polymorphic region (5-HTTLPR) had different transcriptional efficiencies. In particular, the basal transcriptional activity of the long variant is more than twice that of the short form, and choriocarcinoma cells containing the latter produce 30-40% lower concentrations of 5-HTT mRNA. In vitro studies showed that the differences in 5-HTT mRNA synthesis result in different 5-HTT expression and 5-HT cellular uptake, 6 thus allowing us to hypothesize that individual differences of antidepressant response to comparable SSRIs bioavailability could be related to different in vivo expression level of 5-HTT.
Recently, the addition of pindolol (a mixed ␤-adrenoreceptor and 5-HT 1A antagonist) has been proposed as an augmentation therapy for nonresponders or partial responders to SSRIs. 7, 8 This effect of pindolol is probably related to its ability to block 5-HT 1A autoreceptors, thus preventing a negative feedback of 5-HT at somatodendritic level 9 and suggesting that the activation of 5-HT 1A autoreceptors could modulate the clinical effect of the SSRIs-induced 5-HTT blockade.
These data prompted us to test the hypothesis that allelic variation of 5-HTT gene expression was linked to antidepressant response to fluvoxamine alone and/or to augmentation with pindolol in a population of severely depressed patients with psychotic features.
Subjects and methods

Subjects and treatment
One hundred and two inpatients, consecutively admitted to the Research Center for Mood Disorders of the S. Raffaele Hospital in Milan for a major depressive episode with psychotic features, were included in the study. Patients should meet the DSM-IV 11 criteria for diagnosis. Exclusion criteria were: additional diagnoses on axis I; mental retardation on axis II; pregnancy, major medical and neurological disorders; medical contraindications to the use of fluvoxamine or pindolol; treatment with irreversible MAOIs or slow release neuroleptic drugs in the last month before admission. Physical examinations, laboratory tests and electrocardiograms were performed at admission.
Patients gave their written informed consent to participate in the study and underwent a 7-day run-in period with a single-blind placebo. After the run-in period, all patients had the 21-item Hamilton Depression Rating Scale (HDRS) 12 score Ͼ21 and no improvement in psychotic features was observed. No response to placebo was observed.
Patients were randomly assigned to two groups by a computer-generated schedule and treated with fluvoxamine 300 mg day 
Data collection
Plasma levels of fluvoxamine were determined at the third week of treatment (after 2 weeks of stable 300 mg day −1 ) by high-performance liquid chromatography as described elsewhere. 13 Three patients, with fluvoxamine plasma levels exceeding the mean value of the sample ± 1.96 s.d., were removed from the study, to avoid extreme differences in the bioavailability of the drug influencing the clinical response. Obviously, this procedure is far from an ultimate solution to this problem. However, it may represent an acceptable approximation, given the impossibility of obtaining levels at the central target sites of the drug.
Genomic DNA was extracted from whole blood and target DNA was amplified by polymerase chain reaction (PCR) and detected as previously described.
14 Genotyping was performed blind to the clinical course of illness. The 21-item HDRS was administered by trained raters, blind to genotyping, at baseline and every week thereafter until week 6; whenever possible, the same rater conducted admission and following ratings for each patient.
Data analysis
Clinical and demographic characteristics were compared between groups with two-way analysis of variance, with genotype and treatment as between subjects factors, or with Chi-square test, as appropriate. Changes in HDRS scores over time (ie fluvoxamine response either with or without pindolol) were analyzed with a three-way repeated measures analysis of variance, with time (ie medication effect) as within subjects factor, and with genotype and treatment (ie placebo or pindolol) as between subjects factors. Posthoc comparisons were performed with Newman-Keuls test; homogeneity of variances at outset was tested using Levene's test. Response rates were compared between groups with Chi-square test or Fisher exact test.
Results
Genotype frequencies, as well as clinical and demographic characteristics of the sample, are shown in Table 1 . No significant difference was observed. As expected, fluvoxamine plasma levels did not significantly differ among treatment and genotype groups. Statistical analysis showed a significant difference of HDRS scores (corresponding to fluvoxamine response) according both to genotypes and to treatment ( Figure  1) .
Homogeneity of variances at outset was successfully tested for HDRS scores (F = 1.16; d.f. 5,93; P = 0.336). A three-way repeated measures analysis of variance on HDRS scores showed a highly significant time effect (F = 329.57; d.f. 6,558; P Ͻ 0.0001), a significant effect of genotype (F = 3.49; d.f. 2,93; P = 0.0346), and a highly significant effect of treatment (F = 15.44; d.f. 1,93; P = 0.0002). Genotype per time interaction (F = 2.55; d.f. 12,558; P = 0.0028), treatment per time interaction (F = 2.45; d.f. 6,558; P = 0.0239), and genotype per treatment interaction (F = 4.25; d.f. 2,93; P = 0.0172) were all significant. In addition the three-way (ie genotype per treatment per time) interaction was significant (F = 2.07; d.f. 12,558; P = 0.0173), thus supporting the hypothesis that genotype might condition the antidepressant response over time according to treatment (ie fluvoxamine alone or with pindolol).
Post hoc comparisons did not show any significant difference at baseline. In patients treated with fluvoxamine alone (Figure 1a ) both l/l and l/s subjects had significantly better scores than s/s starting from week 2 to week 6 (P = 0.0283 and P = 0.0012 at week 2, respectively; P Ͻ 0.0001 for all other comparisons). In patients treated with fluvoxamine plus pindolol, no significant difference among genotype groups was found (Figure 1b) . A comparison between treatment groups showed that the addition of pindolol abolished the differences of response to fluvoxamine observed in fluvoxamine plus placebo group. In particular, in fluvoxamine plus pindolol group, s/s patients had significantly better scores from week 1 to week 6 (P = 0.0061 at week 1; P Ͻ 0.0001 for all other comparisons), l/s patients at week 1 and 2 (P = 0.0244 at week 1 and P = 0.0469 at week 2, respectively), and l/l patients at week 2 (P = 0.0005) when compared with fluvoxamine plus placebo patterns.
Discussion
To our knowledge, our results provide the first clinical evidence that allelic variation of 5-HTTLPR may affect the response to SSRIs at equal bioavailability, thus also supporting our first hypothesis regarding the existence of a 'SSRI dose -5-HTT amount -clinical effect' connection.
The results herein reported can be summarized as follows: (1) in our sample of delusional depressed the response to fluvoxamine alone seems to be related to 5-HTTLPR genotypes; (2) these differences were abolished by the addition of pindolol to fluvoxamine, a current augmentation strategy both in non-psychotic and psychotic depression. Moreover, statistical analysis suggested these differences are not related to differences either in clinical and demographical features of the sample or in fluvoxamine plasma levels.
The transcriptional activity of the short and long variants of the 5-HTT promoter gene has proven to be different in vitro, leading to significant changes in the 5-HTT expression and 5-HT uptake. 6 Furthermore, previous studies reported a decreased number of 5-HTT binding sites in post-mortem brain tissue and in platelets of depressed patients. 15 It is conceivable that differences in expression and activity of 5-HTT may account for the differences we observed in our patients treated with fluvoxamine alone. Intriguingly, these differences disappeared combining fluvoxamine and pindolol. In the absence of data on the amount of brain 5-HTT in human subjects with different 5-HTTLPR genotypes, these findings must be cautiously regarded.
Nevertheless, these results can be tentatively explained in the light of previous data suggesting that the 5-HT increasing action of SSRIs is limited by a negative feedback at somatodendritic level. In particular, the self-inhibition of serotonergic transmission seems to be attributable to the activation of 5-HT 1A somatodendritic autoreceptors (which are blocked by pindolol) due to the SSRIs-stimulated increase in extracellular 5-HT at the level of raphe nuclei. 9 Moreover, 5-HTT mRNA is particularly abundant in the dorsal raphe nucleus (DRN) 16 which is thought to be the initial site of this negative feedback, as its 5-HT neurons project to frontal cortex and are very sensitive to self-inhibition mediated by 5-HT 1A autoreceptors.
If the expression of 5-HTT (and, therefore of SSRIsbinding sites) is reduced (as in s/s patients), the same dose of SSRI could cause a greater increase in extracellular 5-HT at somatodendritic level, then leading to an enhancement of self-inhibition in the projection areas mediated by an overstimulation of 5-HT 1A autoreceptors. That could explain poor clinical response to fluvoxamine alone in s/s patients. Furthermore, the addition of a 5-HT 1A antagonist such as pindolol abolished this genotype effect, probably by preventing the increased autoinhibition of serotonergic firing at the same site.
However, given in vivo expression studies are lacking in humans, alternative hypotheses cannot be excluded. For example, 5-HT could be released also via reversal of the transporter, likewise dopamine, GABA and glutamate, [17] [18] [19] or the genotype effect we observed could be linked to (or mediated by) still unknown neurobiological mechanisms. Our results support the hypothesis that the therapeutic response to antidepressant drugs acting on 5-HTT may be related to allelic variation of functional 5-HTTLPR, thus suggesting, in turn, that genotyping of this region might become a promising tool to individualize pharmacological treatment of depression. On the other hand, they may represent a further contribution toward a better understanding of the underlying mechanisms of a nonresponse to antidepressant treatment.
However, it is clear that replication of our finding, in independent samples and using different serotonergic antidepressants, is critical. In fact, the possibility has to be considered that our finding might be linked to undetected population stratification (or, simply, to the size of our sample). Nevertheless, it may be seen as a further proof of the central role that 5-HTT blockade plays in SSRIs' antidepressant effect.
